Management of Excessive Anticoagulation or Bleeding

Seminars in Vascular Medicine

Volumn 3, Issue 3, 2003, Pages 279-284

  Makris, Michael ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bleeding; Concentrate; Fresh frozen plasma; Vitamin K; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR CONCENTRATE; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; VITAMIN K GROUP;

ANTICOAGULATION; BLEEDING; DRUG WITHDRAWAL; HIGH RISK POPULATION; HUMAN; INTERNATIONAL STANDARD UNIT; REVIEW; RISK FACTOR; TREATMENT INDICATION;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; DRUG TOXICITY; HEMORRHAGE; HUMANS; PLASMA; RISK; VITAMIN K; WARFARIN;

EID: 0142072115     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44464     Document Type: Review

References (29)

1. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579S-589S
2. Breukink-Engbers WG. Monitoring therapy with anticoagulants in The Netherlands. Semin Thromb Hemost 1999;25:37-42
3. Saito H. Normal hemostatic mechanisms. In: Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis, 3rd ed. Philadelphia: WB Saunders; 1996:23-52
4. Kumar S, Haigh JR, Tate G, et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance. Br J Haematol 1990;74:82-85
5. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston FE. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemostasis 1997;77:477-480
6. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-328
7. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996;124:970-979
8. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428
9. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-99
10. Cosgriff SW. The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinaemia during anticoagulant therapy. Ann Intern Med 1956;45:14-22
11. Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coag Fibrinolys 1993;4:739-741
12. White R, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995;122:40-42
13. Crowther MA, Julian J, McCarthy D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-1553
14. Watson HG, Baglin TP, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001;115:145-149
15. Weibert RT, Le DT, Kayser SR, Rapaport SI. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 1997;126:959-962
16. Pendry K, Bhavnani M, Shwe K. The use of oral vitamin K for reversal of over-warfarinization. Br J Haematol 2001;113:839-840
17. Makris M, Watson HG. The management of coumarin-induced over-anticoaguladon. Br J Haematol 2001;114:271-280
18. Sherry HGM, Backhouse G, Bentley DP, Routledge PA. Effective reversal of warfarin induced excessive anticoagulation with low dose vitamin K. Thromb Haemostasis 1992;67:13-15
19. Whitling AM, Bussey HL, Lyons RM. Comparing different routes of phytomenadione for reversing excessive anticoagulation. Arch Intern Med 1998;158:2136-2140
20. Nee R, Doppenschmidt D, Donovan SJ, Andrews TC. Intravenous versus subcutaneous vitamin K in reversing excessive oral anticoagulation. Am Coll Cardiol 1999;83:286-288
21. Hung A, Singh S, Tate RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol 2000;109:537-539
22. Baglin TP, Rose PE. Guidelines on oral anticoagulation. Br J Haematol 1998;101:374-387
23. Arzneimittelkommission der deutschen Arzteschaft. Beriplex HS 250. Beriplex HS 500. Paul-Ehrlich-Institut (PEI). Deutsches Arzteblatt 1994;91:2056
24. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991;28:3-5
25. McNeill SA, Ewing JC, Wallace WA, Stewart LH. Venous infarction of a testicle following factor IX concentrate (DEFIX). Br J Haematol 1998;101:210
26. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002;116:619-624
27. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001;115:998-1001
28. Hedner U. Novoseven as a universal haemostatic agent. Blood Coag Fibrinolys 2000;11:S107-S111
29. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (Novoseven) in healthy volunteers receiving acenocoumarol to an international normalised ratio above 2.0. Blood Coag Fibrinolys 1998;9:741-748